Susceptibility, tumor progression and resistance
Pujana’s Lab

DESCRIPTION

Targeting cancer complexity at origin and progression

Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).

Group members

Miquel Angel Pujana

Group leaders

Principal investigator

Francesca Mateo

Researchers

Research assistant

Roderic Espín

Young investigators

PhD student

Lara Ruiz

Young investigators

PhD student

Arzoo Shabbir

Young investigators

PhD student

Luís Alfaro

Young investigators

PhD student

Publications

Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types

11 de February de 2021/in Pujana's Lab/by miguel

Sci Transl Med. 2021 Feb 10;13(580):eabc4465. doi: 10.1126/scitranslmed.abc4465. ABSTRACT Among the pleotropic roles of transforming growth factor-β (TGFβ) signaling in cancer, its impact on genomic stability is least understood. Inhibition of TGFβ signaling increases use of alternative end joining (alt-EJ), an error-prone DNA repair process that typically functions as a “backup” pathway if double-strand break […]

RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors

2 de February de 2021/in Pujana's Lab/by miguel

J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105. ABSTRACT Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes considerably increase breast and ovarian cancer risk. Given that tumors with these mutations have elevated genomic instability, they exhibit relative vulnerability to certain chemotherapies and targeted treatments based on poly (ADP-ribose) polymerase (PARP) inhibition. However, the molecular mechanisms […]

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

16 de July de 2020/in Pujana's Lab/by miguel

Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15. ABSTRACT PURPOSE: We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. METHODS: Retrospective cohort data on 18,935 BRCA1 and 12,339 BRCA2 female pathogenic variant carriers of […]

Immune Cell Associations with Cancer Risk

5 de July de 2020/in Pujana's Lab/by miguel

iScience. 2020 Jul 24;23(7):101296. doi: 10.1016/j.isci.2020.101296. Epub 2020 Jun 20. ABSTRACT Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in immune and/or stromal cell contents in the corresponding tissue. Predicted target […]

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

3 de July de 2020/in Pujana's Lab/by miguel

JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134. ABSTRACT IMPORTANCE: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. OBJECTIVE: To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 […]

Research Projects

The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.

Collaborations

CIMBA – Consortium of Investigators of Modifiers of BRCA1/2

https://cimba.ccge.medschl.cam.ac.uk/

Lobular Breast Cancer

https://lobsterpot.eu/

BRCA1 breast cancer

Khokha Lab

https://medbio.utoronto.ca/faculty/khokha

Hakem Lab

https://medbio.utoronto.ca/faculty/hakem

Maxwell Lab

https://www.bcchr.ca/cmaxwell

Serra Lab

https://vhio.net/biosketch-violeta-serra/

Cancer biology

Schramek Lab

https://schramek.lunenfeld.ca/

Li Lab

https://lilab.smhs.gwu.edu/

Barcellos-Hoff Lab

https://barcelloshofflab.ucsf.edu/principal-investigator

Cancer genetics

De Cid Lab – GCAT

http://www.gcatbiobank.org/

LAM research

Johnson Lab – LAM UK

https://www.nottingham.ac.uk/medicine/people/simon.johnson

Elżbieta Radzikowska

National Tuberculosis and Lung Diseases Research Institute, Poland

Kwiatkowski Lab

https://www.kwiatkowskilab.org/

AELAM

https://www.aelam.org/

VHIR

https://vhir.vallhebron.com/en/research/pneumology

Molina Lab

https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/

Susceptibility, tumor progression and resistancePujana’s Lab

DESCRIPTION

Miquel Angel Pujana

Group leaders

Francesca Mateo

Researchers

Roderic Espín

Young investigators

Lara Ruiz

Young investigators

Arzoo Shabbir

Young investigators

Luís Alfaro

Young investigators

CONTACT US

Susceptibility, tumor progression and resistance
Pujana’s Lab